Trial Profile
An Open-Label, Multi-Center, Expanded Treatment Protocol of Quizartinib in Adult Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3-ITD Mutations
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Quizartinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Expanded access; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 14 Apr 2020 Status changed from recruiting to completed.
- 26 Nov 2018 New trial record